.1, D46.9, D46.A, and D46.B) from Oct 2015 to Mar 2023. No diagnosis of MDS/acute myeloid leukemia (AML) or use of higher-risk MDS or AML medication before their respective index diagnosis dates were allowed. Lines of treatment were determined by the
Search Results
HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data
Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Eric Padron, and David Sallman
CGE23-071: Real World Data on the Implementation of a Hereditary Hematological Myeloid Malignancy Workflow: Experience of a Single Academic Medical Center
Moon Ley Tung, Athena Puski, Jennifer L Stinson, Nicole Huser, and Madeline VanDerGraaf
Background: Hereditary myeloid malignancy syndromes (HMMS) are increasingly recognized in adult patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Timely diagnosis of HMMS is critical to ensure appropriate bone marrow
JNCCN CE Offerings
/4/13 Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review Expiration Date: 7/7/13 Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time? Expiration Date: 8/7/13 Androgen Deprivation Therapy
CE Offerings
CME/CE articles published in previous issues of JNCCN: Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review Expiration Date: 7/7/13 Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready
Developmental Therapeutics for Myelodysplastic Syndromes
Aung Naing, Lubomir Sokol, and Alan F. List
. 22. Foran J Paquette R Copper M . A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed or are not eligible for conventional chemotherapy [abstract] . Blood 2002 ; 100
Epigenetic Modulation in Hematologic Malignancies: Challenges and Progress
Constantine S. Mitsiades and Kenneth C. Anderson
-sensitive ovarian tumors . Nat Med 2003 ; 9 : 568 - 574 . 54. Melki JR Vincent PC Clark SJ . Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia . Cancer Res 1999 ; 59 : 3730 - 3740 . 55. Hegi ME Liu L Herman JG
Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database
Guru Subramanian Guru Murthy, Aniko Szabo, Laura Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Sameem Abedin, and Ehab Atallah
Background Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) that is characterized by chromosomal translocation t(15;17) with fusion of PML-RARA genes and cell-cycle arrest at the promyelocyte stage. 1 APL
Treatment Disparities Faced by Undocumented Workers From Low- and Middle-Income Countries in the United States With Hematologic Malignancies
Sara E. Nunnery, Andrew E. Fintel, W. Clay Jackson, Jason C. Chandler, Michael O. Ugwueke, and Mike G. Martin
urgent leukapheresis, a bone marrow biopsy was performed and a diagnosis of acute myeloid leukemia (AML) was made. He was started on induction chemotherapy with cytarabine, idarubicin, and cladribine (7+3+5). 4 The final bone marrow biopsy revealed high
Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy
Sophia Koo and Lindsey R. Baden
lymphoproliferative disorders . Blood 2002 ; 100 : 3121 – 3127 . 51. Ho AY Pagliuca A Kenyon M . Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia
The NCCN 2019 Annual Congress: Hematologic Malignancies
Robert W. Carlson
neoplasms. Also in the congress, blood cancer experts described updates in treatment strategies for Hodgkin lymphoma, advances in first-line acute myeloid leukemia management, and progress in personalized therapeutic approaches in myelodysplastic syndromes
